Living With Hemophilia A
Using the activity risk scale to help plan your activities
For more information about the risks of certain activities, read the following publication: Anderson A, Forsyth A. Playing it Safe. New York, NY: National Hemophilia Foundation; 2005.
No matter how well-conditioned you are and no matter what level of skill you have, various activities carry risks.
Individuals with hemophilia A can be at an increased risk when playing sports or exercising. Understanding these risks can help you make good choices about your participation in certain activities.
Select a risk level to see how certain activities rank on a scale from 1 (safe) to 3 (dangerous).
It is important to note that Level 1, Level 1.5, and Level 2 indicate that the health benefits of these particular activities may outweigh the associated risks. All sports that are rated as Level 2.5 and Level 3 are dangerous and are not recommended for people with bleeding disorders.
| 1 Safe |
1.5 Safe to Moderate |
2 Moderate |
2.5 Moderately Dangerous |
3 Dangerous |
|---|---|---|---|---|
| Very Low Risk | Low Risk | Medium Risk | High Risk | Very High Risk |
| Aquatics Archery Fishing Frisbee Golf Hiking Snorkeling Stationary bike Swimming Walking | Bicycling Body sculpting Circuit training Frisbee golf Pilates Spinning Treadmill Weightlifting/resistance training | Aerobics Bowling Cardio kickboxing Dance Rock climbing(indoor) Roller-skating Running/jogging Stepper Tennis Yoga | Baseball Basketball Cheerleading Horseback riding Kayaking Mountain biking River rafting Soccer Softball Surfing | Boxing Football Hockey (all) Lacrosse Motorcycling/ motocross racing Powerlifting Rock climbing (natural) Rugby Scooter(motorized) Wrestling |
Important Safety Information
ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.
Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.
Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.
Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.
Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).
Rapid administration of a FVIII concentrate may result in vasomotor reactions.
Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.
Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.
The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.
Please see full Prescribing Information for ALPHANATE.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.